← Fundnode · Learn

State hub · Washington healthcare

Healthcare MCA in Washington — funders, SBA vs MCA math, practice profiles.

Washington healthcare is shaped by three forces almost no other state shares: the academic and research density of UW Medicine and Fred Hutchinson Cancer Center, the Eastside private practice cluster serving the Microsoft/Amazon/Google commercial-insurance employer base, and a state regulatory environment that grants MD and DO licensure parity with rare administrative friction. WA also has the most rigorous pharmacy and outpatient prescribing oversight regime in the Pacific Northwest. HB 1874, the WA Commercial Financing Disclosure Law, is pending and scheduled to take effect in 2027 — meaning AZ-style funder-direct diligence still matters for now. Here is the honest map.

By Keerthana Keti10 min read

Washington healthcare market context

Washington HB 1874, the WA Commercial Financing Disclosure Law, was passed in 2024 and is scheduled to take effect January 2027. Once in force, HB 1874 will require non-bank commercial financing providers to disclose APR-equivalent, total cost of capital, payment amount and frequency, and prepayment charges on offers to WA businesses — modeled closely on CA SB 1235 and NY's NYDFS rule. As of mid-2026, however, WA remains a non-disclosure state, meaning opaque-pricing MCA funders still write business freely here. Healthcare practices receiving WA MCA offers in 2026 should explicitly request APR-equivalent and total cost of capital disclosures — reputable funders will provide both; opaque operators will dodge. This dynamic will change in January 2027. The Washington Medical Commission and Washington State Board of Dental Examiners grant MD and DO licensure with rare administrative friction and treat physician assistants and ARNPs with one of the most expansive scope-of-practice authorities in the country. The downstream effect on practice economics: independent and small-group practices in WA can staff more flexibly than in scope-restrictive states like FL or TX, which improves margin profiles and SBA debt service coverage ratios. WA Apple Health Medicaid managed care reimburses through five MCO plans with payment cycles of 45-75 days. Per-visit rates are roughly mid-pack nationally; the state's Medicaid expansion under the ACA produced unusually high coverage rates, so even commercial-heavy practices see meaningful Apple Health volume. UW Medicine and Fred Hutchinson Cancer Center anchor one of the most research-heavy academic medicine ecosystems in the country. Independent specialty practices in the surrounding Seattle metro (oncology, hematology, immunology, GI, neurology) benefit from research-overflow referrals and unusually well-insured patient populations; these practices typically have strong commercial-payer mix, short AR cycles, and high goodwill valuations. Practice sizes we see most often: solo practitioners ($40K-$150K, often SBA Express), Eastside group practices ($200K-$1M via SBA 7(a)), Seattle and Bellevue multi-location specialty and DSO consolidations ($1M-$5M via Live Oak, BHG, or specialty medical lenders).

Top funders for Washington healthcare practices

Live Oak Bank

Strong WA healthcare SBA 7(a) volume despite no Seattle-area office. Particularly active on Bellevue/Eastside dental specialty and dermatology acquisitions, plus Seattle multi-specialty group expansions. Specialty underwriting depth wins on goodwill-heavy WA practice transactions.

Bankers Healthcare Group

Specialty medical bank term loans up to $500K. Strong WA volume among established independent practices in Eastside, particularly Microsoft/Amazon/Google-employer-adjacent specialty groups wanting 2-3 week underwriting vs SBA timing.

Lendeavor

Healthcare practice acquisition specialist (dental, vet, optometry). Active in Eastside dental specialty acquisitions and Seattle vet practice acquisitions. Often wins on speed for buyers with clean cash flow coverage.

Bluevine

LOC for established WA practices with 12+ months and 625+ credit. APR 14-22% materially beats MCA cost for working capital needs; the LOC stays available after initial draw, which fits WA practice cash flow patterns.

Washington cities and healthcare markets

  • Seattle — UW Medicine, Fred Hutchinson Cancer Center, Seattle Children's, and Virginia Mason Franciscan Health anchor academic and specialty referral networks. Independent specialty practices in Capitol Hill, Queen Anne, and First Hill are research-adjacent and skew commercial-heavy with short AR cycles (35-50 days). Deal sizes $200K-$1M typical.
  • Bellevue / Eastside — Highest concentration of private practice density per capita in WA. Microsoft, Amazon, Google, and T-Mobile commercial insurance plans drive premium reimbursement; dermatology, GI, orthopedic, fertility, and concierge primary care concentrate here. Cash-pay aesthetics is a meaningful growth segment. Deal sizes skew large ($300K-$1.5M); strong SBA profile.
  • Spokane — Providence Sacred Heart and MultiCare Deaconess anchor Eastern WA regional referrals. Smaller practice sizes than Puget Sound metros; mixed payer mix with meaningful Apple Health Medicaid percentages. Cross-border patient flow from northern ID. SBA Express and Bankers Healthcare Group dominate deal flow.
  • Tacoma / Pierce County — MultiCare Tacoma General and CHI Franciscan St. Joseph anchor regional referrals. Military medical population (Joint Base Lewis-McChord) creates significant TRICARE patient base; specialty practices serving TRICARE families face distinctive billing and AR dynamics. Mid-size practices common.
  • Vancouver / Clark County — Portland metro overflow market with WA tax advantages for owners and employees. PeaceHealth Southwest anchors regional referrals. Growing dental specialty and primary care concentration as Portland-based practitioners relocate to WA to capture state income tax savings. Deal sizes $100K-$500K typical.

The funding math, in Washington terms

A 4-physician GI specialty group in Bellevue doing $500K/month in revenue (85% commercial / 10% Medicare / 5% Apple Health) needs $500K to add an in-office endoscopy suite (procedure room buildout, two scopes, sterilization equipment, anesthesia services contract setup) and to hire a CRNA. - Live Oak Bank SBA 7(a) over 10 years: $500K at prime + 2.5-3% (~10.5-11% in mid-2026), monthly payment ~$6,800. SBA 7(a) is purpose-built for procedure-suite buildouts; in-office endoscopy materially improves practice margin profile (avoids ASC facility fee leakage), which strengthens SBA debt service coverage analysis. Closes in 35-45 days. - Bankers Healthcare Group practice term loan: $500K over 7 years at ~13-15% fixed, monthly payment ~$9,400. Closes in 2-3 weeks; no UCC blanket lien on practice assets. Fits if practice wants speed plus structural flexibility. - Bluevine LOC: $250K cap (max), would cover only part of the need. APR 14-22%; revolving structure useful for any working capital portion of the buildout and CRNA ramp. - $500K MCA at 1.27 factor over 12 months: $635K payback, ~$1,765/day ACH. WA HB 1874 disclosure does not take effect until January 2027, so the APR-equivalent (roughly 55-65%) may not be on the offer letter unless requested. Daily payment would consume roughly 12% of average daily revenue during the endoscopy ramp period when procedure volume is still building. Best fit: Live Oak SBA 7(a) for cheapest cost of capital and right structure for procedure-suite buildouts. BHG if the 2-3 week timing advantage matters and the practice prefers to avoid SBA blanket lien on existing equipment. MCA is the wrong tool for any WA GI specialty buildout above $100K — the cost gap relative to SBA crushes long-term practice equity, and the GI procedure-volume ramp timeline misaligns with MCA daily payback structure.

Related reading for Washington healthcare practitioners

Frequently asked questions

Frequently asked questions

When does WA HB 1874 commercial financing disclosure take effect?
WA HB 1874 was passed in 2024 and is scheduled to take effect January 2027. Until then, WA remains a non-disclosure state. Once in force, HB 1874 will require non-bank commercial financing providers to disclose APR-equivalent, total cost of capital, payment amount and frequency, and prepayment charges on offers to WA businesses — modeled closely on CA SB 1235 and NY's NYDFS rule. Healthcare practices should expect opaque-pricing MCA funders to either disclose or exit WA in late 2026 as the effective date approaches.
How does the UW Medicine and Fred Hutchinson research ecosystem affect independent practice funding?
UW Medicine and Fred Hutchinson Cancer Center anchor one of the most research-heavy academic medicine ecosystems in the country, and the surrounding Seattle metro hosts an unusually strong independent specialty practice cluster handling research-overflow referrals (oncology, hematology, immunology, GI). These independent practices typically have strong commercial-payer mix, short AR cycles, and high goodwill valuations — they are among the most attractive SBA and specialty medical lender credits in the Pacific Northwest. Live Oak and BHG both actively call on UW/Fred Hutch alumni networks.
Why is Eastside (Bellevue/Redmond/Kirkland) such a strong SBA market?
The Eastside hosts the densest concentration of large-employer commercial insurance plans (Microsoft, Amazon, Google, T-Mobile, Expedia) in WA. These plans reimburse 15-25% above national specialty fee schedule averages; AR cycles for Eastside specialty practices run 30-45 days. Combined with above-median patient cash-pay capacity for aesthetics and concierge services, Eastside specialty practices typically have practice valuations and debt service coverage ratios that qualify cleanly for SBA 7(a) acquisitions and expansions. Live Oak particularly favors these credits.
How does WA's expansive ARNP and PA scope of practice affect practice funding?
Washington grants ARNPs full independent practice authority and PAs unusually broad scope-of-practice, which lets WA primary care and specialty practices staff with mid-level providers more flexibly than scope-restrictive states like FL or TX. The downstream effect on funding: practices can scale revenue per physician partner higher and run leaner staffing, which improves margin profiles and SBA debt service coverage ratios. Lenders increasingly view WA practices with strong ARNP/PA leverage as among the most attractive primary care credits nationally.
What is a typical WA specialty practice MCA rate when one is actually appropriate?
B-paper (12+ months, $40K+/mo, 600+ credit): 1.24-1.36 at direct funders pre-HB 1874. A-paper (24+ months, $75K+/mo, 650+ credit): 1.18-1.28 reachable. Once HB 1874 takes effect in January 2027, expect rate compression similar to what occurred in NY and NJ post-disclosure (roughly 1-2 points tighter on the high end as opaque operators exit). Until then, always shop funder-direct to establish baseline pricing before working with a broker.